Sangamo Therapeutics shares rose after the company said the outcome of a recent successful interaction with the Food and Drug Administration provided a clear regulatory pathway to accelerated approval ...

This indicates that while drug development has become more complex and expensive ... Yet, the goals of reduced costs and ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) and keeping the ...

Technologies for the rapid and efficient testing of small molecules and biologics have greatly accelerated drug discovery.

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

DBV and FDA are in general agreement that the confirmatory study will need to demonstrate the effectiveness of the Viaskin ...

A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.

Interim data from Otsuka's trial of sibeprenlimab indicates a significant reduction in proteinuria in IgA nephropathy ...

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing innovative treatments for food allergies and other serious medical conditions. Their flagship product, the Viaskin ...

Innovative AI architect Rishabh Shanbhag drives ethical, cross-industry transformation through cutting-edge enterprise ...